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Background: RELIS is a Norwegian network of four regional medicine-information and 
pharmacovigilance centers where pharmacists and clinical pharmacologists provide feedback 
to health care professionals in spontaneous drug-related questions and adverse drug-reaction 
(ADR) reports published in a question–answer pair (QAP) database (the RELIS database) and 
the Norwegian ADR database, respectively.
Objective: To describe the potential of RELIS’s dual service to improve detection and com-
munication of drug-safety problems.
Materials and methods: We searched the RELIS database for QAPs about ADRs with use of 
the Norwegian ADR database as a reference. We also searched the Norwegian ADR database 
for reports that used the RELIS database as a reference. Both searches were limited to the years 
2003–2012. We then selected the example of pregabalin and drug abuse after the marketing of 
Lyrica in Norway in September 2004 to illustrate RELIS’s potential to detect new drug-safety 
information through a limited number of QAPs and ADR reports.
Results: A total of 5,427 (26%) of 21,071 QAPs in the RELIS database concerned ADRs. 
QAPs from this database were used as references in 791 (4%) of a total of 22,090 reports in the 
Norwegian ADR database. The Norwegian ADR database was used as a reference in 363 (7%) 
of 5,427 QAPs that concerned ADRs. Between September 2004 and September 2008, RELIS 
received eleven questions and 13 ADR reports about suspicion of Lyrica (pregabalin) and dif-
ferent aspects of abuse.
Conclusion: RELIS processes data through two databases that facilitate communication about 
ADRs. Our service also has the potential to detect new drug-safety problems with a limited 
number of questions and ADR reports.
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Introduction
Location, organization, and staff competence are of importance for a pharmacovigilance 
center.1 In some countries, the centers are associated with health authorities or drug-
 regulatory agencies. In other countries, national centers cooperate with a network of local 
centers, part of the health care system, and/or medical universities.2 Pharmacovigilance 
should ideally be closely linked to drug regulation, because governmental support is 
needed for national and international coordination and communication.1 Furthermore, 
drug-regulatory agencies exchange drug-safety information with pharmaceutical com-
panies, and personnel with regulatory training facilitate both national and international 
affairs in pharmacovigilance. However, drug safety is not only a regulatory task but 
represents an important health matter. Local  pharmacovigilance centers have a link 





to clinical practice and the ability to increase the quality 
of adverse drug-reaction (ADR) reports. Competence in 
pharmacy and medicine are often found in local centers that 
facilitate communication about drug safety with health care 
professionals. Irrespective of the organization, spontaneous 
reporting remains a cornerstone of pharmacovigilance, and 
is of major importance for signal detection. To facilitate 
the latter, spontaneous ADR reports are processed through 
national and international databases.3
The Norwegian model includes cooperation between the 
Norwegian Medical Agency and RELIS. RELIS is a network 
of four regional medicine-information and pharmacovigi-
lance centers. The centers are localized at university hospitals 
in Norway, where pharmacists and clinical pharmacologists 
answer spontaneous drug-related questions from health care 
professionals (mainly physicians and pharmacists) working 
in hospitals, hospital pharmacies, general practice, and com-
munity pharmacies.4,5 ADRs are the most common category 
of questions to RELIS, and represent a substantial part of our 
question–answer pair (QAP) database (the RELIS database). 
Use of spontaneous ADR reports from the Norwegian ADR 
database as references is a possibility in these QAPs. RELIS 
also handles spontaneous ADR reports from health care 
professionals, and gives individualized feedback that may 
refer to QAPs from the RELIS database. ADR reporting 
is mandatory for physicians and dentists in Norway, and 
includes reporting on suspicion of fatal and life-threatening 
ADRs, ADRs that lead to or prolong hospital stay, and ADRs 
that are new or unexpected. ADR reporting is voluntary for 
all other health care professionals and consumers. RELIS 
does signal detection by a qualitative analysis of individual 
case-safety reports (ICSRs). Signal detection including 
disproportional analysis is made by the Norwegian Medical 
Agency. Extensive literature search, pharmacists’ and clini-
cal pharmacologists’ involvement, and short response time 
(within 10 calendar days) are important in RELIS’s com-
munication about ADRs. Therefore, the mutual use of the 
aforementioned databases is useful for this communication. 
In particular cases, detection of new drug-safety information 
through a joint medicine-information and pharmacovigilance 
service like RELIS is a possibility, as described here.
Materials and methods
We searched the RELIS database for QAPs about ADRs with 
use of the Norwegian ADR database as a reference. We 
also searched the Norwegian ADR database for reports that 
used the RELIS database as a reference, using a  preexisting 
module for searches of the reporter-feedback field, which 
contains the references. Both searches were limited to the 
years 2003–2012. We then selected the example of pregabalin 
and suspicion of drug abuse after the marketing of Lyrica® 
(Pfizer, New York, NY, USA) in Norway in September 2004 
to illustrate RELIS’s potential to detect new drug-safety 
information through a limited number of QAPs and ADR 
reports. All QAPs and ADR reports involving pregabalin 
from September 2004 until September 2008 were analyzed 
for any ADR describing aspects of drug abuse or drug depen-
dence without restricting the analysis to selected Medical 
Dictionary for Regulatory Activities terms. Duplicates 
between ADR reports and QAPs were excluded based on 
comparison of the information provided in each report or 
question.
Results
Figure 1 shows the results. A total of 5,427 (26%) of 21,071 
QAPs in the RELIS database concerned ADRs. QAPs from 
this database were used as references in 791 (4%) of a total 
of 22,090 reports in the Norwegian ADR database. The 
Norwegian ADR database was used as a reference in 363 (7%) 
in a total of 5,427 QAPs that concerned ADRs. Lyrica 
(pregabalin) was marketed in September 2004 in Norway. 
In July 2005, RELIS received the first question concerning 
pregabalin abuse. Two subsequent ADR reports in January 
2006 about drug abuse were followed by a question to RELIS 
in March 2006 suspecting a particular problem among patients 
with opioid addiction and psychiatric diseases. Descriptions of 
problems with dose escalation, craving, and withdrawal reac-
tions were found in questions and ADR reports during 2007 
and 2008. Eleven questions complemented 13 ADR reports 
in September 2008 (4 years after marketing) by including a 
wide spectrum of behaviors indicating drug abuse, eg, the 
enthusiasm and satisfaction with pregabalin prescriptions 
shown by former and current drug abusers.
Discussion
RELIS’s dual service with medicine-information and pharma-
covigilance could be of importance for two purposes: to meet 
expectations for feedback in ADR reporting and drug-related 
queries, and to detect drug-safety problems in particular 
populations. The mutual use of the two databases as references 
may at first glance seem limited, but one has to remember that 
both sources are based on spontaneous and not systematic data 
collection. In 2003, 47 ADR reports used the RELIS database 
as a reference compared to 73 in 2012. In 2003, 0 QAPs used 




reLIS reporting of drug-safety problems
the Norwegian ADR database as a reference compared to 56 
in 2012. Therefore, mutual use of the two ADR information 
sources has the potential to increase due to data accumulation. 
Importantly, the staff at RELIS process data to both databases, 
and are thereby alert to suspicion of drug-safety problems, 
although the number of questions and/or ADR reports is 
small. The example of pregabalin illustrates that a particular 
drug-safety issue associated with subgroups of patients could 
be detected. Four years after marketing in Norway, 13 ADR 
reports and eleven questions to RELIS depicted a drug-safety 
problem with pregabalin later described internationally.6–9 This 
is in contrast to the experience that pregabalin is safe, based 
on results of clinical studies and patient reporting.10,11 
Pregabalin has also been controversial among physicians 
in Norway, with discussions of its value in the treatment of 
neuropathic pain and generalized anxiety weighed against 
its potential for abuse.12,13 Based on staff discussions within 
the RELIS network and close communication with the 
Norwegian Medical Agency, matters of concern like the case 
of pregabalin and abuse were submitted to the Norwegian 
Pharmacovigilance Advisory Board for further national 
and international discussions. Furthermore, in 2013 the 
Norwegian Pharmacovigilance Advisory Board advised the 
Norwegian  Medical Agency to make pregabalin a controlled 
drug, and its prescription status will be evaluated.14 
The use of qualitative analysis of individual ICSRs and 
questions about ADRs on suspicion of drug-safety problems 
as described here is well known to pharmacovigilance cen-
ters and medicine-information centers. Furthermore, data-
bases with ICSRs can be studied with systematic methods.15 
The present description focused on how the RELIS network 
with common electronic resources facilitates communication 
about ADRs, and has the potential to detect new drug-safety 
problems through an arbitrary method based on a limited 
number of questions and ADR reports.
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Figure 1 the regional Medicines Information and Pharmacovigilance Centres (reLIS) in Norway provide feedback to health care professionals on spontaneous drug-related 
questions and adverse drug-reaction (ADr) reports published in a question–answer pair (QAP) database (the reLIS database) and the Norwegian ADr database, respectively.
Notes: Mutual use of the two ADr information sources has the potential to increase knowledge of drug safety due to data accumulation. the example of pregabalin and 
suspicion of drug abuse after the marketing of Lyrica in Norway in September 2004 is used to illustrate reLIS’s potential to detect new drug-safety information through a 
limited number of QAPs and ADr reports.
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